Compare Neurocrine Biosciences Inc (NBIX) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Rocket Lab USA Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Rocket Lab USA Inc trades at $68.21 (market cap $43.74B). The key difference: Rocket Lab USA Inc is far larger — about 3× Neurocrine Biosciences Inc's market cap, and Rocket Lab USA Inc is more actively traded (22,892,581 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Rocket Lab USA Inc for 29 Days on average.
| NBIX | RKLB | |
|---|---|---|
Market Cap | $14.36B | $43.74B |
Volume | 1,237,180 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $185.50 | $150.23 |
52-Week Low | $123.10 | $39.48 |
Typical Hold Time | 23 Days | 29 Days |
Enterprise Value | $14.37B | $41.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Rocket Lab (RKLB) trades at $68.40, down 4.89% today, amid bearish technical signals despite positive business developments. The company recently secured its largest-ever commercial Electron launch contract with Synspective for 20 missions, expanding its backlog to over 100 launches. Fundamentally, RKLB shows strong revenue growth with $602 million in 2025 and projected $769 million in 2026, though it remains unprofitable with negative margins. Analyst sentiment remains overwhelmingly bullish with 16 buy ratings and a $107 consensus price target, representing significant upside potential from current levels.
Rocket Lab presents a high-risk, high-reward opportunity with substantial growth potential in the expanding space economy offset by persistent losses and competitive threats from SpaceX. The company's expanding launch backlog and Neutron rocket development provide long-term catalysts, but investors must weigh the premium valuation against ongoing cash burn and execution risks in a capital-intensive industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
